Jazz Pharmaceuticals

hideThis article has multiple issues. Please help or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article relies too much on references to primary sources. Please improve this by adding secondary or tertiary sources. (July 2018) (Learn how and when to remove this template message) This article contains content that is written like an advertisement. Please help by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (July 2018) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

Jazz Pharmaceuticals plc

Type	Public company
Traded as	Nasdaq: JAZZ S&P 400 component
Industry	Biotechnology Pharmaceutical
Predecessor	Jazz Pharmaceuticals, Inc. (before the 2012 tax inversion to Ireland)
Founded	March 2005; 16 years ago (2005-03) in California, U.S.
Headquarters	Waterloo Exchange, Waterloo Road, D04 E5W7, Dublin, Ireland
Area served	Worldwide
Key people	Bruce C. Cozadd (Chairman & CEO)
Products	Pharmaceutical drugs
Brands	Xyrem Erwinaze Defitelio FazaClo FazaClo HD Luvox CR Prialt Vyxeos
Revenue	US$1.618 billion (2017)[1]
Operating income	US$528.8 million (2017)[1]
Net income	US$487.8 million (2017)[1]
Total assets	US$5.123 billion (2017)[1]
Total equity	US$2.713 billion (2017)[1]
Number of employees	~1,210 (February 2018)[1]
Website	jazzpharma.com

Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland. It was founded in 2003.^[2] One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales.^[1] In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA).

In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.^[3]

The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).^[4]

Company history & Acquisitions[]

2010–2019[]

On February 18, 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia.^[5] In the following December, a new patent was issued for Sodium Oxybate.^[6]

On September 19, 2011, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge.^[7]

On April 26, 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments).^[8] In September, the company successfully sold its Women's Health business to Meda for $95 million.^[9] In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia.^[10]

In January 2014, the company announced it would acquire the rare disease drug developer and its lead product Defitelio for $1 billion.^[11][12]

In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million.^[13] At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.^[14] As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.^[15]

In August 2019, the company announced it would acquire Cavion Inc. for up to ~$310 million.^[16][17]

2020 onwards[]

In January 2021, Jazz announced it would acquire GW Pharmaceuticals for $7.2 billion ($200.00 in cash and $20.00 in shares of Jazz).^[18][19]

Acquisition history[]

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

References[]